The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor growth (g-rate).
 
Harshraj Leuva
Stock and Other Ownership Interests - AstraZeneca/Merck
 
Mengxi Zhou
No Relationships to Disclose
 
Rumen Stamatov
No Relationships to Disclose
 
Benjamin A. Teply
Consulting or Advisory Role - Hospicom; Lilly; Pfizer/Myovant; Sanofi; SeaGen
Research Funding - Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); QED Therapeutics (Inst)
 
Ta-Chueh Melody Rosenberg
No Relationships to Disclose
 
Carol A. Luhrs
No Relationships to Disclose
 
Prabhjot Singh Mundi
No Relationships to Disclose
 
Yeun-Hee Anna Park
No Relationships to Disclose
 
Susan Elaine Bates
Honoraria - Merck (I)
Consulting or Advisory Role - Akita Biomedical (I); ElmediX; Ipsen; OnKure; Pegascy; Progenics (I); Secura Bio (I); SERVIER
Research Funding - Amgen (Inst); Ipsen (Inst); Merck (Inst); Pfizer; Pfizer (Inst); RenovoRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst)
 
Izak Faiena
No Relationships to Disclose
 
Antonio Tito Fojo
Honoraria - Merck
Consulting or Advisory Role - Akita Biomedical; ElmediX (I); OnKure (I); PEGASCY (I); SERVIER (I)
Research Funding - Ipsen (Inst); Merck (Inst); Pfizer (I); Pfizer (Inst)